Tesamorelin

Tesamorelin binds the GHRH receptor on anterior pituitary somatotrophs, the same receptor used by endogenous GHRH, and its distinguishing feature is resistance to enzymatic inactivation. Native GHRH is cleaved between Tyr1 and Ala2 by dipeptidyl peptidase-4 within minutes; the trans-3-hexenoyl cap on Tyr1 blocks that cleavage, and the non-clinical evaluation of TH9507 published in 2007 reported both DPP-IV resistance and enhanced duration of action relative to unmodified hGRF(1-44)NH₂. Because it acts upstream of the pituitary rather than substituting for growth hormone, endogenous pulsatility and feedback control remain part of the system.

Tesamorelin is not a licensed medicine in the United Kingdom and holds no UK marketing authorisation. It has never been authorised as a medicinal product here, and the EU centralised marketing authorisation application for Egrifta was withdrawn by the applicant in June 2012 after the CHMP indicated it could not reach a positive benefit-risk conclusion. It is approved only in the United States, by the FDA in November 2010, for one narrow indication. UK Peptide Lab supplies tesamorelin solely as a laboratory reference material for in-vitro research use: not for human or veterinary use, not for consumption, and not for any therapeutic purpose. Buyers must be 18 or over and must confirm research-only use. This is regulatory background rather than legal advice, and researchers remain responsible for confirming the rules that apply to their own institution and jurisdiction.

Egrifta is the US brand name for tesamorelin as a prescription medicinal product, so the active molecule is the same but the article is not. A licensed medicine is manufactured, released and labelled to a marketing authorisation with an approved indication and prescribing information behind it. What is supplied here is tesamorelin as a research reagent, batch UKPL-314, measured at 95.937% by HPLC (Janoshik Analytical, 26 October 2026) with the certificate of analysis published on this page. It is not Egrifta, is not a medicine, and is for in-vitro research use only.

All three are GHRH receptor agonists, and the difference is how much of the native sequence they keep and how they resist degradation. Sermorelin is the truncated GHRH(1-29) fragment with no stabilising modification. CJC-1295 is a modified GRF(1-29) analogue, available with or without the DAC linker that gives it a much longer duration. Tesamorelin is unusual in retaining the complete 44 residue GHRH sequence, with resistance coming from a single trans-3-hexenoyl group on Tyr1 rather than from truncation or a linker. Researchers pick tesamorelin when the design calls for a full-length GHRH sequence with DPP-4 resistance, and it is the only one of the three that has ever been through phase 3 trials.

Mean elimination half-life reported in the FDA prescribing information is 26 minutes in healthy subjects and 38 minutes in HIV-infected patients following subcutaneous administration. That is short in absolute terms but dramatically longer than native GHRH, which dipeptidyl peptidase-4 degrades within minutes, and it illustrates why the growth hormone response outlasts the plasma presence of the analogue itself: the readout is pituitary secretion, not the concentration of the secretagogue.

The published human literature falls into two groups. Endocrine pharmacology studies characterised what a DPP-4 resistant GHRH analogue does to secretion patterns, with Stanley and colleagues (Journal of Clinical Endocrinology and Metabolism, 2011) reporting increased basal and pulsatile GH secretion in healthy men without a change in pulse frequency. Clinical trials ran principally in HIV associated lipodystrophy, where Falutz and colleagues (New England Journal of Medicine, 2007) and a later pooled phase 3 analysis reported changes in visceral adipose tissue and circulating IGF-I, with Makimura and colleagues (2012) extending the work to non-HIV subjects with reduced GH secretion. Those findings belong to defined patient populations studied under medical supervision and are reported here as literature background only, not as claims about this product.

Each vial contains tesamorelin as a lyophilised powder, formula C₂₂₁H₃₆₆N₇₂O₆₇S, molecular weight 5135.8 g/mol, CAS 218949-48-5, batch UKPL-314, tested at 95.937% purity by HPLC (Janoshik Analytical, 26 October 2026) with the certificate of analysis published on this page. To reconstitute, inject bacteriostatic water slowly down the inner glass wall of the vial and swirl gently until the solution is clear and colourless. Do not shake or vortex. Allow both vials to reach room temperature first and swab each stopper with alcohol before needle entry.

Tesamorelin is a synthetic analogue of human growth hormone releasing factor, hGRF(1-44)NH₂, developed under the code TH9507, that acts as an agonist at the GHRH receptor. UK Peptide Lab supplies it as a lyophilised powder in 5mg and 10mg vials, batch UKPL-314, measured at 95.937% purity by HPLC (Janoshik Analytical, 26 October 2026). It is sold for in-vitro research use only.

Yes. Tesamorelin is a 44 residue peptide, the full human GHRH sequence with a single trans-3-hexenoyl group attached to Tyr1. Its formula is C₂₂₁H₃₆₆N₇₂O₆₇S with a molecular weight of 5135.8 g/mol and CAS 218949-48-5.

UK Peptide Lab has tesamorelin peptide for sale online in 5mg and 10mg vials, dispatched from the UK. Each batch has its own third-party certificate, and the batch on this listing is UKPL-314. Orders placed before 3pm on a working day are dispatched the same day, with free UK delivery over £69.

Yes. Every batch has a third-party certificate of analysis. Batch UKPL-314 was measured by Janoshik Analytical on 26 October 2026 at 95.937% purity by HPLC, with 5.07mg of tesamorelin per 5mg vial. The certificate is published in the certificate section, so you can check purity and content before ordering.

Tesamorelin is used in endocrine research on GHRH receptor activation, somatotroph pharmacology and endogenous growth hormone secretion. It is also a reference compound for DPP-4 resistance as a peptide stabilisation strategy. It is supplied for laboratory research only.